Implantable therapeutic device
First Claim
1. An ophthalmic drug delivery system comprising:
- a formulation comprising a therapeutic agent that is an inhibitor of complement factor D, the therapeutic agent having a concentration in a solution volume;
an extended release device configured to be implanted in an eye, the device comprising;
a refillable or flushable reservoir formed of a non-permeable material defining a hollow reservoir volume sized to receive the solution volume and defining at least one exit port, wherein the reservoir is configured to adopt an expanded profile configuration after insertion in the eye and introduction of the solution volume into the reservoir and configured to adopt a narrow profile configuration for removal from the eye;
a penetrable barrier positioned in an access port near a proximal end region of the device; and
a rigid porous structure coupled to the at least one exit port of the reservoir and formed of a porous material through which the therapeutic agent passively diffuses into the vitreous of the eye, wherein the rigid porous structure has a release rate, and a porosity P; and
an injector configured to penetrate the penetrable barrier while the device is implanted in the eye to refill or flush the reservoir through the penetrable barrier of the access port with an amount of the formulation, the injector comprising;
a needle having a first lumen and a second lumen;
an injection chamber configured to be in one-way fluid communication with the reservoir via the first lumen; and
a vent chamber configured to be in one-way fluid communication with the reservoir via the second lumen, wherein the vent chamber comprises a resistance to flow substantially lower than a resistance to flow through the rigid porous structure.
1 Assignment
0 Petitions
Accused Products
Abstract
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
-
Citations
17 Claims
-
1. An ophthalmic drug delivery system comprising:
-
a formulation comprising a therapeutic agent that is an inhibitor of complement factor D, the therapeutic agent having a concentration in a solution volume; an extended release device configured to be implanted in an eye, the device comprising; a refillable or flushable reservoir formed of a non-permeable material defining a hollow reservoir volume sized to receive the solution volume and defining at least one exit port, wherein the reservoir is configured to adopt an expanded profile configuration after insertion in the eye and introduction of the solution volume into the reservoir and configured to adopt a narrow profile configuration for removal from the eye; a penetrable barrier positioned in an access port near a proximal end region of the device; and a rigid porous structure coupled to the at least one exit port of the reservoir and formed of a porous material through which the therapeutic agent passively diffuses into the vitreous of the eye, wherein the rigid porous structure has a release rate, and a porosity P; and an injector configured to penetrate the penetrable barrier while the device is implanted in the eye to refill or flush the reservoir through the penetrable barrier of the access port with an amount of the formulation, the injector comprising; a needle having a first lumen and a second lumen; an injection chamber configured to be in one-way fluid communication with the reservoir via the first lumen; and a vent chamber configured to be in one-way fluid communication with the reservoir via the second lumen, wherein the vent chamber comprises a resistance to flow substantially lower than a resistance to flow through the rigid porous structure. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
Specification